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2Abstract
Chronic intestinal pseudo-obstruction (CIPO) represents the most severe form of gastrointestinal
dysmotility with debilitating and potentially lethal consequences. Symptoms can be non-specific,
and result in this condition being diagnosed incorrectly or too late with consequences for morbidity
and even mortality. Thus, the present article aims to provide pediatric and adult gastroenterologists
with an up to date review about clinical features, diagnosis and therapeutic options for CIPO.
Although pediatric and adult chronic intestinal pseudo-obstruction share many clinical aspects
distinctive features can be identified. There is no single diagnostic test or pathognomonic finding of
CIPO, thus a stepwise approach including radiology, endoscopy, laboratory, manometry and
histopathology should be considered in the diagnostic work-up. Treatment of patients with CIPO is
challenging and requires a multidisciplinary effort with participation of appropriately experienced
gastroenterologists, pathologists, dieticians, surgeons, psychologists, and other subspecialists based
on the presence of comorbidities. Current treatment options invariably involve surgery and
specialised nutritional support, especially in children. Medical therapies are mainly aimed to avoid
complications such as sepsis or intestinal bacterial overgrowth and, where possible, restore
intestinal propulsion. More efficacious therapeutic options are eagerly awaited for such difficult
patients.
Key words: Chronic intestinal pseudo-obstruction; clinical manifestations; histopathology;
manometry; nutritional therapy.
3Key Points
 There is no single diagnostic test or pathognomonic findings for CIPO. The main goals of
the diagnostic work up are to exclude bowel mechanical obstruction, to identify underlying
diseases and to understand the pathophysiological features.
 Treatment is challenging and requires a multidisciplinary effort.
 Key objectives in the management of patients with CIPO are to avoid unnecessary surgery,
restore fluid and electrolyte balance, maintain an adequate caloric intake, promote
coordinated intestinal motility and treat bacterial overgrowth.
4Introduction
Chronic intestinal pseudo-obstruction (CIPO) is a rare condition characterized by a severe
impairment of gastrointestinal (GI) propulsion, which results in symptoms suggestive of partial or
complete intestinal obstruction in the absence of any lesion restricting or occluding the intestinal
lumen.1-5 CIPO can involve any segment of the GI tract (although the small bowel and colon are
mainly affected) and represents the most severe form of GI dysmotility with potentially lethal
consequences.2,4 Symptoms can be non-specific with CIPO mistaken for other diseases and
consequently not diagnosed for long periods of time.6,7 The chronicity of the severe digestive
symptoms, the inability to maintain an adequate nutritional status without specialist support, the
suboptimal efficacy of medical treatments, and the limited knowledge of the syndrome by
physicians constitute some of the main factors contributing to the poor quality of life and the high
morbidity and mortality rate of patients with CIPO.6-10
Much like other rare diseases with poorly defined diagnostic criteria, CIPO has a largely unknown
prevalence and incidence.2 One nationwide survey in the U.S. reported that about 100 infants were
born with CIPO every year.11 A more recent nationwide survey in Japan found a prevalence of 3.7
in one million children (1 in 270,000 children younger than 15 years of age) with equal sex
incidence.12 These studies most likely underestimates the true number of new cases per year, as they
do not include patients who develop symptoms of CIPO later in life. In another survey of 378
institutions belonging to the Japanese Society of Gastroenterology, CIPO prevalence in adult
patients was estimated to be 1.0 and 0.8 cases per 100,000 males and females, respectively. The
incidence in the same population was 0.21 and 0.24 cases per 100,000 males and females,
respectively.13
The purpose of this paper is to provide a broad review of CIPO ranging from pediatric to adult age
highlighting selectively the main clinical aspects such as symptoms / signs, diagnosis and
therapeutic options in the different age groups. Deliberately, we did not address the putative
mechanisms underlying severe gut dysfunction as well as the attendant histopathological features
5and the reader is referred to published comprehensive articles on these topics (references 14-57). In
Table 1 we have summarized the classification of CIPO in relation to etiopathogenetic factors.
Disease spectrum
CIPO is not a single clinical entity, rather an umbrella term for a range of different diseases leading
to severe, end-stage gut motor failure. The most severe cases of the CIPO spectrum are those
involving pediatric patients with antenatal (in utero) evidence of multivisceral dilation of the hollow
viscera (e.g. digestive and urinary systems), often characterized by inability to tolerate enteral
feeding and poor prognosis (Figure 1A-B).8,58-60 This clinical subset represents the most common
group of pediatric CIPO patients with diffuse involvement of the GI tract. In these cases, the
neuromuscular abnormalities (either genetic or acquired) of the GI tract do not preclude birth, but
can be severe enough to generate the onset of symptoms in the early newborn period with reported
mortality rates ranging from 10% to 32%.8,58,59
More rarely, some cases appear to be acquired after birth being characterized by a variable period of
normality followed by progression to intestinal failure with bowel (and often urinary tract)
dilatation. In some of the most aggressive forms of acquired CIPO, the histopathological analysis
may detect a massive inflammatory (mainly lymphocytic) neuro-muscular infiltrate, reminiscent of
the autoimmune pancreatic 'insulitis' underlying insulin-dependent diabetes mellitus of the
childhood 25 (Figure 1C-D). These cases of CIPO may respond to an immunosuppressive treatment
if the immune-mediated insult has not completely damaged regulatory cells, i.e. enteric nerves,
interstitial cells of Cajal (ICC), and smooth muscle.34-39
Other cases of pediatric and adult CIPO may occur in patients who experience more insidious mild
and nonspecific symptoms (either 'irritable bowel syndrome’ - or 'dyspepsia’ - like) thought not to
carry a risk to evolve into severe dysmotility. Nonetheless, some of these patients do progress on to
a classic CIPO phenotype over time (Figure 1E-G). We consider them the 'dark-side' of adult CIPO
spectrum, i.e. cases in whom a number of factors, including an altered gut microbiota, intestinal
6epithelial barrier dysfunction, immune dysregulation and other poorly defined mechanisms may
operate, individually or in concert, to impair the neuro-muscular homoestasis.6 Patients with acute
onset of CIPO after abdominal surgery, i.e. mimicking a prolonged postoperative ileus, remain a
largely unexplained subset. Other striking examples are those cases occurring after ileal bypass
performed to treat morbid obesity, suggesting that surgical manipulation may by itself evoke neuro-
myoelectrical abnormalities in predisposed alimentary tracts.61 A synoptic view of this section is
reported in Figure 1.
Clinical findings
CIPO may involve any segment of the GI tract and therefore symptoms can vary from patient to
patient based on the location and the extent of the gut segment involved. Also, extra-intestinal
manifestations and malnutrition contribute to the clinical features.5,7,15,62-64 Prenatal signs are only
detected in about 20% of cases, whereas 50-70% of patients show clinical signs perinatally (i.e.
within the first month of age). Most patients (80%) show clinical manifestations by the first year of
age, while the remaining 20% have sporadic onset during the first two decades of life.8,9,12,58,59 One
study indicated that the median age of symptom onset in adults is 17 years.37
Both pediatric and adult CIPO shares many clinical aspects, although distinctive features can be
identified (Table 2). In any age group, the clinical picture tends to be dominated by abdominal pain
and distension (80%), which are particularly severe during acute episodes of pseudo-obstruction.37
Associated symptoms include nausea and vomiting (75%), constipation (40%), and diarrhea
(20%).6,10,37 Between acute episodes, patients can be minimally symptomatic, or continue to
experience severe proximal (anorexia, early satiety, nausea and vomiting) and distal digestive
symptoms (constipation, diffuse abdominal pain and / or distension).6,8 Prevalence and severity of
acute episodes that recur at irregular intervals vary from patient to patient. Malnutrition is another
significant clinical aspect in any patient with CIPO. This is due to both the limited oral intake,
because ingestion of food generally aggravates symptoms, and the intestinal malabsorption related
7to the altered gut transit, often associated with dilated bowel loops. In about 30% of CIPO patients
small intestinal bacterial overgrowth (SIBO) occurs as a result of intestinal stasis and can cause
diarrhea and steatorrhea.6 Gastroparesis and urinary bladder dysfunction (with or without
megacystis and megaureter) are co-morbidities likely sharing similar pathophysiological
mechanisms with those underlying CIPO.2 Also, because of the frustrating ineffectiveness of most
therapeutic interventions, patients with CIPO may develop depression or other psychological
disorders.65,66
In children, there is a higher risk of colonic and small bowel volvulus secondary to severe
dysmotility and gut dilatation, congenital adhesions or concurrent malrotation.8,59,67-69 Urological
involvement is commonly identified in patients with familial and congenital forms of CIPO,
particularly in the myopathic subgroup, ranging from 36 to 100%.8,70-73 Findings include urinary
retention secondary to bladder atony, hydronephrosis, vesicoureteral reflux, and recurrent urinary
tract infections. Megacystis on antenatal ultrasound has been reported in up to 59% of CIPO and
this finding may require caesarean delivery.72,73 The megacystis can be associated with a
microcolon, a phenotype referred to as megacystis-microcolon-intestinal-hypoperistalsis syndrome.4
Other syndromic form of CIPO are represented by the mitochondrial disorders which in a large
adult series account for 19% of all CIPO patients. They are characterized by severe intestinal
dysmotility, poor nutritional status and neurologic manifestations, e.g. peripheral neuropathy (with
mild to moderate hypoesthesia), proprioceptive ataxia, progressive external ophthalmoplegia with
ptosis and hearing loss.2 GI manifestations are common at presentation and positive family history
together with the progressive neurological and nutritional deterioration should alert clinicians to
search for mitochondrial disorders.42,43,74,75
Secondary systemic forms (i.e. related to underlying conditions) of CIPO are more common in adult
patients in whom they occur at much older age.2 A proximal muscle weakness may indicate the
presence of polymyositis and dermatomyositis. Scleroderma is usually associated with skin
abnormalities, while the suspicion of a paraneoplastic syndrome should prompt investigations
8aimed at uncovering an occult malignancy of the lung, ovary and breast. Finally, forms of CIPO
associated with Chagas' disease are common in Latin America and are characterized by
combination of dysphagia and cardiomyopathy.6,7,11,25,26,32,33,76
Diagnosis
The diagnosis of CIPO is mainly clinical. The diagnostic work up of both children and adults with
suspected CIPO has the following goals: 1) rule out mechanical causes of bowel obstruction. This
can be achieved by abdominal computed tomography (CT) or plain X-ray; 2) identify any
underlying diseases by an accurate laboratory test profile; 3) evaluate the possibility of a drug-
induced CIPO-like presentation (e.g. opioids, tricyclic antidepressants, anti-cholinergic agents, anti-
Parkinsonian agents, phenothiazines); and 4) understand the pathophysiological features which may
direct management or bear prognostic information in selected cases (particularly by performing GI
manometry in cases without bowel dilation). Thus, a stepwise approach (as outlined above) is
commonly recommended in CIPO and includes radiology, endoscopy, laboratory, manometry and
histopathology.
Radiology
A plain radiograph of the abdomen usually identifies the typical signs of intestinal obstruction, i.e.
air-fluid levels and dilated bowel loops.2,12,59 Air-fluid levels are better visualized in the upright
position, but lateral views can be useful. In symptomatic patients without these radiographic
findings, other conditions (e.g. chronic constipation, irritable bowel syndrome and functional
dyspepsia) should be considered.
Fluoroscopic studies should be performed using water-soluble contrast solutions in order to avoid
complications related to barium concretions and, at the same time, enhance hydration and transit of
intestinal contents. Upper GI series with small bowel follow-through can reveal dilated bowel loops
(often involving the stomach and duodenum) with very slow transit, although the latter finding may
9not be detectable in some pediatric cases. Intestinal malrotation may be identified in up to a third of
children with CIPO.8 Less common findings include diverticulosis of the small intestine (in 53% of
patients with mitochondrial neurogastrointestinal encephalomyopathy, MNGIE, and 42% of
scleroderma), and intestinal pneumatosis.2
Contrast medium radiologic tests have been recently superseded by dedicated enterography with
high-resolution CT77 or MRI, which more accurately detect mechanical obstruction and intestinal
adhesions. Cine-MRI is emerging as a non invasive, radiation-free method for assessing and
monitoring GI motility particularly in the pediatric population.78,79
Excretory urograms should be performed in patients with urinary symptoms, since neuro-
myopathies may affect both the GI tract and urinary system. A chest CT may be necessary to
exclude small cell lung cancer in adult patients with suspected paraneoplastic CIPO. Finally,
imaging of the brain can identify leukoencephalopathy in CIPO related to MNGIE.43,74,75
Endoscopy
Upper GI endoscopy may be useful to exclude a mechanical occlusion of the proximal small
intestine as well as to collect duodenal biopsies in cases where celiac disease or eosinophilic
gastroenteropathy are suspected.3 Colonoscopy can be used to rule out mechanical obstruction and
decompress the large intestine, although this manoeuvre rarely provides long-term satisfactory
results.80 The wireless motility capsule measures intraluminal pH, temperature, and pressure;
however, the role of this technique in the diagnosis of CIPO has not been established yet and its use
is thought to be possibly hazardous when a mechanical obstruction has not been definitely ruled
out.81
Laboratory tests
Laboratory exams are aimed to uncover secondary causes of CIPO. Blood tests for diabetes mellitus
(i.e. hemoglobin A1C and / or postprandial blood glucose concentration), celiac disease (anti-tissue
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transglutaminase IgA and anti-deamidated gliadin peptides IgG), connective tissue and skeletal
muscle disorders (anti-nuclear antibody, anti-double-stranded DNA and SCL-70, creatine
phosphokinase, aldolase), and hypothyroidism should be performed. Other tests include serology
for Chagas’ disease, urinary catecholamines for pheochromocytoma, and enteric neuronal
autoantibodies (anti-Hu or type 1 anti-neuronal nuclear antibodies) in patients with suspected
paraneoplastic syndrome. Urinary porphyrins should be assayed in patients with severe, otherwise
unexplained abdominal pain. A complete blood cell count, electrolytes, albumin, liver enzymes,
vitamin B12, fasting cortisol, inflammatory indexes (C-reactive protein and erythrocyte
sedimentation rate) are useful in all cases.66 Patients receiving parenteral nutrition (PN) should be
carefully monitored with particular attention to fluid, electrolytes and circulating levels of trace
elements. In patients with symptoms and signs suggestive of an underlying mitochondrial disorder,
serum lactate and thymidine phosphorylase activities should be performed. If thymidine
phosphorylase activity is markedly reduced / absent and nucleosides are increased, then thymidine
phosphorylase (TYMP) (in MNGIE), and polymerase DNA-gamma (POLG) (in sensory ataxic
neuropathy dysarthria and ophthalmoparesis) gene mutations should be tested.74,75
Manometry
Intestinal manometry can be useful to define the pathophysiological (neuro-muscular) mechanisms
involved in CIPO (e.g. neuropathy or myopathy), although it has a low diagnostic specificity and in
most pediatric and adult patients does not influence treatment. Nonetheless, intestinal manometry
can differentiate mechanical from functional forms of sub-occlusion, provided that the organic
cause is at an early stage.6,7,10,62,63,82-86 The presence of postprandial, prolonged, high pressure, non-
propagated contractions is a pattern suggestive of a recently occurred mechanical obstruction.5,7,10,11
A neuropathy is characterized by contractions showing a normal amplitude, although with
uncoordinated pattern5,7,10,11 (Figure 2), whereas coordinated contractions with a reduced amplitude
are indicative of an enteric myopathy. However, a careful interpretation is mandatory since low-
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amplitude contractions could be secondary to the inability of the manometric catheter to register
non-occlusive contractions when bowel loops are dilatated.2 Antroduodenal manometry has been
applied extensively in children in order to assess prognosis, response to treatment and tolerance to
oral feeding.82-84 In children with chronic symptoms suggestive of CIPO, a normal manometry
essentially excludes CIPO and should lead to the consideration of emotional or factitious disorders
(e.g. Munchausen syndrome by proxy).85,86 Amiot et al. have identified abnormal esophageal
manometry in 73% (51% with severe ineffective dysmotility) adult CIPO cases.87 Similar findings
have been also documented in paediatric cases of CIPO.59 Notably, only esophageal motor disorders
had a significantly negative predictive value in terms of survival, home PN requirement, and
inability to maintain sufficient oral feeding, suggesting the presence of a more generalized
disease.87 Also, esophageal manometry may have diagnostic value in CIPO associated with
scleroderma. Anorectal manometry is indicated when the clinical picture is characterized by
intractable constipation and marked colonic dilatation, suggestive of Hirschsprung's disease.2 A
careful manometric assessment of the entire GI tract, including the colon, has been deemed helpful
in helping to plan for an isolated or a multivisceral transplantation in the most severe forms of
pediatric CIPO.11
Histopathology
Collection of gut full-thickness biopsies is aimed at providing clinicians with a histopathological
correlate which may unravel abnormalities related to: a) extrinsic and/or intrinsic neurons
controlling gut functions; b) the ICC networks; and c) enteric smooth muscle cells. Changes
affecting these cellular systems are tightly linked to the pathophysiology of CIPO and may have
prognostic and sometimes therapeutic implications. 88,89 Minimally invasive procedures, e.g.
laparoscopic surgery or - very recently - endoscopic approaches (for example natural-orifice
translumenal endoscopic surgery), have shown a high diagnostic yield and safety.90 In addition,
guidelines proposed by the Gastro 2009 International Working Group have helped to find consensus
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about technical aspects (including tissue collection and processing) and histopathological reporting
of results in a variety of gut neuro-muscular disorders, including CIPO.24,44
In the absence of clinical guidelines, we suggest that ideal CIPO patients who should be referred to
laparoscopic surgery for full-thickness biopsies fall into these two major categories: 1) idiopathic
cases characterized by an acute onset likely of post-infectious origin; 2) patients with progressive,
rapidly evolving forms of CIPO who are not under treatment with opioids and do not respond to any
therapeutic options. In contrast, CIPO patients with severe pain, not uncommonly treated with
opioids, should not undergo intestinal biopsy. In those cases it is advisable to taper down opioids
and change with other non-opioidergic analgesic compounds. This measure is directed to avoid
useless and often misleading histopathological analysis. In CIPO cases with a clear origin (i.e.
secondary forms of CIPO), tissue sampling may be less clinically meaningful as many systemic
diseases are known to affect the gut neuro-muscular layer.
Natural history
A severe clinical course can be expected for both pediatric and adult patients with CIPO when an
underlying treatable disease is not identified.6,62-64,71 In a single-centre study of 59 adult patients
with idiopathic CIPO followed up for a long time (13 years), it was demonstrated that the average
time between the first sub-occlusive episode and the diagnosis of CIPO was 8 years, with 88% of
patients undergoing an average of 3 unnecessary surgical procedures.6 Similar rates of questionable
surgery are seen in the pediatric setting.59 The digestive symptoms worsened over time with
abdominal pain becoming intractable or responsive only to major analgesics (e.g. opioids - always
used parsimoniously and with extreme caution in our own experience) in approximately 25% of
cases.6 Most patients had oral feeding restrictions, while 30%-50% of patients needed long term
PN.6,62,63 A study by Amiot et al., which examined all patients with CIPO on PN at home, revealed
that the lowest mortality was associated with the ability to restore oral feeding and with the
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presence of symptoms before 20 years of age, while an increased mortality was associated with the
presence of scleroderma.62
Manometric parameters, such as inadequate or absent motor response to meals, absence of
migrating motor complex (MMC) during fasting, and generalized hypomotility have been shown to
be predictive of poor outcome in patients with CIPO.62,84 Finally, detection of esophageal
dysmotility in CIPO seems to have negative prognostic implications in terms of mortality and need
for home PN.87 In children with CIPO, a myopathic etiology, coexisting urinary involvement, and
concurrent intestinal malrotation are poor prognostic factors.8 In both adults and children, the risk of
death is increased by the absence of a specialist team and in the early phases after the diagnosis of
intestinal failure has been established.91
Therapy
Treatment of patients with CIPO is challenging and requires a multidisciplinary effort. The
management of both children and adults with CIPO should be directed to avoid unnecessary
surgery, restore fluid and electrolyte balance, maintain an adequate caloric intake, promote
coordinated intestinal motility, and treat complications e.g. sepsis, SIBO and associated symptoms.
In general, current therapeutic approaches are not very effective; however, recent advancement in
nutritional, pharmacological and surgical treatment has helped to improve the management of
patients with CIPO.2,4,5,7
Nutritional support
Patients with CIPO are often malnourished, due to malabsorption and insufficient food intake.
Patients with sufficient intestinal absorption capacity should be encouraged to take small, frequent
meals (5-6 / day), with an emphasis on liquid calories and protein intake, while avoiding high-fat
and high-residue (fiber containing) foods. Carbohydrate containing foods, rich in lactose and
fructose, may worsen abdominal bloating and discomfort.3 Vitamin levels, i.e. A, D, E and K as
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well as B12 and folic acid, should be supplemented when needed. In cases of inadequate oral
intake, enteral nutrition with standard non-elemental formula may be considered. In children,
extensively hydrolysed and elemental formulas are often empirically used to facilitate intestinal
transit and absorption.4,5,92 Before a permanent feeding tube is placed, a trial with a nasogastric or
nasojejunal feeding tube should be attempted using an enteral formula at a rate sufficient to provide
an adequate caloric support.91,93,94 When delayed gastric emptying is present, bypassing the stomach
and directing the feeding into the small intestine is generally preferred. Jejunal feeding tubes were
tolerated in all patients with manometrically detectable MMC vs. 33% of those without. Enteral
nutrition should be started with a slow infusion given continuously or, preferably, in a cyclical
manner (during the night).3
In the most severe cases, PN is necessary to maintain nutritional support and an adequate level of
hydration.93-94 If patients are exclusively dependent on PN, they should receive approximately 25
kcal / kg / day, and lipids should approximately supply 30% of total parenteral calories with 1.0-1.5
g / kg / day of proteins and dextrose covering the remaining caloric amount.93-94 Complications of
PN, including liver failure, pancreatitis, glomerulonephritis, thrombosis and sepsis, are frequent
causes of morbidity and mortality in any form of pediatric and adult CIPO.91,93 Individualized PN
formulations with minimal amount of intravenous lipids can help reducing metabolic complications.
A long-term PN does not seem to be associated with a significant increase in morbidity and
mortality in CIPO.93 A retrospective analysis of 51 adult patients receiving PN for an average of 8.3
years showed 180 episodes of catheter-related sepsis, 9 of acute pancreatitis, 5 encephalopathy, and
4 patients progressing to cirrhosis.62 Oral intake was a major independent factor associated with
better survival; thus, patients receiving PN should be allowed and encouraged to maximize oral
intake as tolerated.93,96
Pharmacologic therapy
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The main aim of pharmacological treatment in patients with CIPO is to promote GI propulsive
activity, thereby improving oral feeding, decreasing symptom severity, and minimizing SIBO.2-4
The efficacy and main features related to various drugs, such as erythromycin, metoclopramide,
domperidone, somatostatin analogues (octreotide and lanreotide), cholinesterases inhibitors
(neostigmine and pyridostigmine), serotoninergic agents (such as 5-hydroxytryptamine receptor 4 -
5-HT4 - agonists, e.g. prucalopride), prostaglandins and gonadotropin-releasing hormone analogues
(leuprolide), have been reported in a number of pediatric and adult CIPO studies (Table 3).97-113
Erythromycin is a macrolide antibiotic mimicking the prokinetic hormone motilin that induces
phase III of the MMC. It has shown to be effective (at a dose of 1.5-2 g/day in adults or 3-5
mg/kg/dose in children) in accelerating gastric emptying and improving symptoms of CIPO in case
reports.4,97 Metoclopramide and domperidone are two orthopramides which exert their prokinetic
effects via type 2 dopamine receptor antagonism and increasing acetylcholine release from
myenteric neurons. Although widely used in patients with functional gut disorders,7 there are no
clinical data regarding their use in CIPO. In addition, metoclopramide has a boxed warning by the
Food and Drug Administration due to the risk of tardive dyskinesia.98 Octreotide, a long-acting
analogue of somatostatin, is known to evoke phase III of the MMC in the small intestine of patients
with scleroderma-related CIPO.99 Subcutaneous octreotide at a dose of 50 mcg/day resulted in a
significant beneficial effect by relieving bacterial overgrowth in those patients.99 Further studies
confirmed its efficacy showing reduction of nausea, vomiting, bloating, and abdominal pain, in a
subset of idiopathic CIPO.100 The acetylcholinesterase inhibitor neostigmine has proven efficacy in
colonic decompression in adult and pediatric acute colonic pseudo-obstruction.101 Repeated use was
successful in an adult patient with colonic pseudo-obstruction, although chronic use in children with
CIPO has not been reported.102 The longer acting pyridostigmine has also been used with success in
adult patients with CIPO.103 Among the newly discovered highly selective 5-HT4 receptor agonists,
prucalopride has shown high bioavailability and lack of major interactions with other drugs as it is
not metabolized by the cytochrome P3A4.104 Prucalopride exerts a significant enterokinetic effects
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105 and a recent randomized, controlled trial on CIPO patients (3 patients had visceral myopathy; 1
visceral neuropathy; all treated with 2-4 mg once daily and followed for 48 weeks), showed
beneficial symptomatic effects and lower use of analgesic drugs.106 Although the sample size was
very small, the results of this study lend support to future multicenter controlled trials.
SIBO is known to cause mucosal inflammation, which further impairs GI motility thereby
contributing to nausea, bloating and abdominal distension.2,107-112 Various antibiotic regimens have
been recommended.110 The treatment of choice usually involves the use of non-absorbable
antibiotics, such as rifaximin.111 Nonetheless, most clinicians use 1- to 2-week rotation of broad-
spectrum antibiotics such as amoxicillin and clavulanic acid, gentamicin, and metronidazole, often
combined with an antifungal compound (e.g., nystatin or fluconazole) followed by antibiotic-free
periods.2 Notably, amoxicillin-clavulanate has been shown to combine antibiotic and enterokinetic
properties in children.112
Non-narcotic pain modulators, such as tricyclic antidepressants and serotonin-norepinephrine
reuptake inhibitors, should be used with caution in CIPO patients due to their significant side effects
(i.e. constipation and / or drowsiness). Starting with low doses followed by gradual increase is
advisable to optimise the beneficial / side effect ratio. Gabapenentinoids (gabapentin and
pregabalin) as well as peripherally acting μ-opioid receptor antagonists (PAMORAs) may represent 
promising alternatives to antidepressants; however studies in patients with CIPO are lacking. If
visceral pain is untreatable, an extremely careful and cautionary use of opiates may be attempted. In
children with CIPO and significant abdominal pain, transdermal buprenorphine (5 mcg / h), a μ- 
partial agonist and κ- and δ-opioid receptor antagonist, has shown adequate pain relief in 3 out of 4 
patients.113
In CIPO characterized by histopathological signs of marked inflammation / immune response
within myenteric ganglia or throughout the neuromuscular tract, immunosuppressive drugs (e.g.,
steroids and azathioprine), might be an effective therapeutic options.34,35,38 Treatment of secondary
forms of CIPO is mainly directed toward the underlying diseases (e.g., scleroderma, paraneoplastic
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syndrome, endocrine related disorders and many others) in addition to gut-directed therapy such as
antibiotics, prokinetics and laxatives.
Endoscopic and Surgical therapy
Decompression of distended GI segments via intermittent nasogastric suction, rectal tubes or
endoscopy in both adults and children is an important therapeutic target.2,3,114 In some cases a
“venting” enterostomy,115 typically placed endoscopically in the intestine, may be necessary.
Recently, repetitive colonoscopic decompression has been successfully used as a bridge therapy
before surgery in a pregnant woman with CIPO.116 In adult patients needing multiple endoscopic
decompression, percutaneous endoscopic colostomy has been recently proposed as a feasible
therapeutic option since it leads to durable symptom relief without risk of surgical intervention.117
The role of surgery in CIPO has been debated over the years. Although its use may be indicated as a
tool to collect gut biopsy specimens for histopathology, the need for surgical therapy is sometimes
required in emergency situations (massive bowel distension and perforation / ischemia). In a
retrospective study on 63 adult patients there was an overall postoperative mortality rate of 7.9%,
while CIPO-related re-operation rate was 66% at 5 years.118,119 In children palliative procedures
such as feeding / venting gastrostomies and jejunostomies are mainly used to relieve symptoms in
half of the patients. 9,120,121 It is important to keep in mind that when a surgical procedure is
performed in a CIPO patient, full-thickness biopsies should be obtained and processed in dedicated
centres.
Transplantation
Intestinal transplantation (isolated or multivisceral) is thought a reasonable therapeutic alternative
for patients with CIPO who experience serious complications of PN (e.g. liver failure or recurrent
sepsis arising from a central venous catheter). Other indications to transplantation are the inability
to obtain venous access for PN and a poor quality of life while on PN.95 Patients with CIPO account
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for approximately 9% of the total intestinal transplants in both adults and children.122-125 Patients
with CIPO should be evaluated for urological abnormalities and antibiotic prophylaxis for urinary
tract infections is often required following transplant in these patients.
The development of new immunosuppressive agents such as tacrolimus and novel induction agents
(basiliximab, alemtuzumab, daclizumab and anti-lymphocyte globulins) have been associated with
an increased overall survival rate and reduced graft rejection rate.126,127 Complications include acute
rejection, opportunistic infections, e.g. cytomegalovirus and Epstein-Barr virus, and surgical
morbidity including wound infections, stoma-related complications, graft ischemia, intestinal
perforations, delayed gastric emptying, intestinal obstruction and biliary tract dilatation.
In the presence of gastric involvement, modified multivisceral transplantation (stomach-duodenum-
pancreas plus small bowel) should be performed, even though some reports described the possibility
to overcome this issue by transplanting the bowel and modifying surgically the stomach in order to
facilitate gastric emptying.127 In children, PN-related liver failure represents an indication for
combined transplant (liver and bowel), but a full multivisceral transplantation (modified
multivisceral graft plus liver) is rarely required. While isolated small bowel and liver-bowel
transplantation have reasonable long term-results, multivisceral transplant should be performed only
in very selected cases and in experienced centers. A study by the University of Miami including 98
adult patients undergoing multivisceral transplantation showed patient and graft survival rates of
49% and 47%, respectively, at a 5-year follow up.125 Italian experiences in adult patients with CIPO
showed that isolated intestinal transplantation performed with different surgical approaches (in
order to reduce the delayed post-surgical gastric emptying) had patient survival rates of 70% at 5
years.127 These results are comparable to those of intestinal transplant in patients with underlying
diseases distinct from CIPO.128-129 The same data have been reported by the United Network for
Organ Sharing in children transplanted for CIPO with a 5-year survival rate of 57%, which is
comparable to the overall survival rates for intestinal transplant.123 These data were also recently
confirmed by an Italian study with a reported survival rate for recipient of intestinal grafts, in any
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combination, of 75% at 2-year follow up.130 Notably, the catch-up growth seen in children
following liver transplantation has not been demonstrated in children with intestinal transplantation.
This is probably related to the severity of the illness at the time of presentation and the use of
intense immunosuppression, including long-term corticosteroids.122
Concerning extra-digestive organ transplant, the allogeneic haematopoietic stem cell transplantation
(AHSCT) can be used to restore thymidine phosphorylase enzyme function which is the key
biochemical deficit in patients with MNGIE. However, so far the results of AHSCT at a 10-year
follow up show that only about 30% of transplanted MNGIE patients are alive. This finding
prompted research to focus on alternative tissue source of thymidine phosphorylase.131 Based on
recent data displaying that the liver has high thymidine phosphorylase expression, we have recently
transplanted a MNGIE patient with promising results.132
Conclusions
CIPO is a rare and severe condition resulting in a marked impairment of GI motility with the
appearance of a mechanical obstruction, without any detectable mechanical cause. Although still a
challenge for most clinicians and surgeons, the future of CIPO may be more promising than one
would expect thanks to a number of important achievements. First, less invasive diagnostic tests,
such as cine-MRI and even endoscopic approaches for full thickness biopsy sampling are novel
tools that are expected to facilitate identification and investigation of CIPO patients. Second, the
classification of enteric neuro-ICC-myopathies and guidelines for tissue processing and analysis
represents a hallmark for tissues analysis aimed to identify novel targeted therapeutic options.
Third, many prokinetic agents are in the pharma pipeline ready to be tested in clinical trials. Fourth,
intestinal transplantation is improving as confirmed by recently published studies. In conclusion,
the advancements so far obtained and those expected in the next years are likely to shed light on
CIPO patients, their management and related therapeutic options.
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Tables
Table 1. Etiology and classification of CIPO.
Primary Secondary Familial forms
 No demonstrable
etiopathogenetic causes
 Neurological disorders
 Metabolic diseases
 Paraneoplastic syndromes
 Neurotropic viruses
 Autoimmune disorders
 Celiac disease
 Neuro-muscular disorders
 Radiation enteritis
 Endocrinological
disorders
 Drugs
 Autosomal dominant
 SOX 10*
 Autosomal recessive
 RAD21*
 SGOL1*
 TYMP*
 POLG*
 X-Linked
 FLNA*
 L1CAM*
Notes: *, denotes mutation(s) to the indicated genes. FLNA, filamin; L1CAM, L1 cell adhesion
molecule; POLG, polymerase DNA gamma; RAD21, cohesin complex component; SGOL1,
shugoshin-like 1; SOX10, SRY-BOX 10; TYMP, thymidine phosphorylase.
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Table 2. Main similarities and differences of CIPO in children and adults.
Children Adults
Etiology Mainly idiopathic Half of cases are secondary to
acquired diseases.
Histopathology Myopathies and neuropathies Mainly neuropathies.
Symptom onset In utero, from birth or early infancy
with 65-80% of patients symptomatic
by 12 months of age
Median age of onset at 17 years.
Clinical features Occlusive symptoms at birth and/or
chronic symptoms without free
intervals
Urological involvement is commonly
encountered ranging from 36-100%
pediatric case series
High risk of colonic and small bowel
volvulus secondary to severe gut
dilation, dysmotility, congenital
bridles or concurrent malrotation
Chronic abdominal pain and
distension with superimposed
acute episodes of pseudo-
obstruction.
Urinary bladder involvement not
so often reported
Natural history Myopathic CIPO, urinary
involvement and concurrent intestinal
malrotation are poor prognostic
factors
The ability to restore oral feeding
and the presence of symptoms <
20 years of age is associated with
a low mortality; while, systemic
sclerosis and severe/diffuse
esophageal and intestinal
dysmotility are associated with a
high mortality
Diagnostic approach Specialized tests (e.g. intestinal
manometry) often difficult to
perform; non-invasive, radiation-free
imaging tests are warranted
Various methodological
approaches usually starting from
endoscopy and radiological tests
up to more sophisticated
functional exams
Nutritional therapy To ensure normal growth
extensively hydrolysed and elemental
formulas are often empirically used to
facilitate intestinal absorption
To improve nutritional status and
prevent malnutrition
Pharmacological therapy Small number / sample size controlled
trials
Small number / sample size
controlled trials; few conclusions
can be drawn for most drugs.
Surgical therapy Venting ostomies (although
characterized by high complication
rates) possibly helpful; surgery as a
'bridge' to transplantation may be
indicated in highly selected cases
Venting ostomies can be helpful;
resective surgery may be
indicated in accurately selected
patients (i.e. cases with proven
segmental gut dysfunction)
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Table 3. Compounds used for the treatment of CIPO in isolated cases or in small series of pediatric
and adult patients.
Drug and study Type of study Number and
type of patients
Dose and period
of treatment
Results Side effects
Erythromycin
Emmanuel et al. APT 2004 Retrospective case
series
15 adults 1.5-2 g/day, oral
or i.v.
6 responders (4
myopathy)
Not reported
Metoclopramide No reported studies ----------- ---------- ---------- --------
Domperidone No reported studies ----------- ---------- ---------- --------
Octreotide
Soudah et al. N Eng J Med
1991
Verne et al. Dig Dis Sci
1995
Case series
Prospective case
series
5 adults with
scleroderma
related CIPO and
SIBO
14 adults
100 mcg/day sc
50 mcg/day sc,
20-33 weeks in
association with
erythromycin
reduces SIBO
and improved
symptoms
5 responders
Not reported
Not reported
Neostigmine
Calvet et al. Am J
Gastroenterol 2003
Case report 1 adult with
chronic colonic
pseudo-
obstruction with
autonomic
paraneoplastic
neuropathy
2 mg i.v. every 6
hours
Improvement
of abdominal
distension and
discomfort and
enteral diet
could be
resumed
Not reported
Pyridostigmine
O’Dea et al. Colorectal Dis
2010
Case series 7 adults 10 mg b.i.d. and
increased if
required (max 30
mg) orally
7 responders Not reported
Prucalopride
Emmanuel et al. APT 2012 RCT cross-over
trial
4 adults 2-4 mg 3 responders Not reported
Antibiotics No reported studies ---------- ------------ --------- ----------
Non-narcotic pain
modulators
No reported studies ---------- ------------ --------- ----------
Buprenorphine
Prapaitrakool et al. Clin J
Pain 2012
Case Series 4 children 10-15 mcg/h,
transdermal, 1-3
years
3 responders Pruritus and
erythema on
the application
site
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Figure Legends
Figure 1
Synoptic view of the CIPO spectrum.
A-B: illustrate the most severe pediatric cases with antenatal (in utero) evidence of multivisceral
dilation (ultrasound picture A - from ref 60) i.e. often gut (B) and urinary system, commonly
associated with an extremely poor prognosis.
C-D: exemplify the CIPO phenotype with a rapid progression to intestinal dilatation (± urether /
bladder) and failure often occurring as a result of an anamnestically reported gastroenteritis.
Specifically, C depicts one of such case with massive bowel dilatation at the operative room and
histopathology (inset to figure D) revealed an intense inflammatory (mainly lymphocytic)
neuropathy (hence, myenteric ganglionitis. Alkaline phosphatase antialkaline phosphatase
immunohistochemical technique using specific anti-CD8 monoclonal antibodies to identify a subset
of T lymphocytes).
E-G: are representative examples of another phenotype of the syndrome which may be observed in
patients who experience more insidious mild and nonspecific symptoms progressing up to a classic
CIPO over time. E shows a markedly distended abdomen of a 32-year old male patient who
presented with a sub-occlusive episodes after some years of unspecific (dyspeptic-/irritable bowel
syndrome-like) symptoms. Note the evident air-fluid levels detectable in up-right position at a
conventional plain abdominal X-ray (F and G, antero-posterior and latero-lateral view,
respectively).
Figure 2
Manometric findings in CIPO.
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A: illustrates a monotonous pattern of phasic and tonic contractions in the small bowel of a 3-year
old boy with a congenital CIPO. No migrating motor complexes (MMC) were detected during a 4-
hour fasting study.
B: shows an abnormal migration of the phase 3 of the MMC with a simultaneous component in the
duodenum in a 7-year old girl affected by a non-congenital form of CIPO.
